CA2837126A1 - Canine influenza recombinant virus, preparation method therefor and application thereof - Google Patents
Canine influenza recombinant virus, preparation method therefor and application thereof Download PDFInfo
- Publication number
- CA2837126A1 CA2837126A1 CA2837126A CA2837126A CA2837126A1 CA 2837126 A1 CA2837126 A1 CA 2837126A1 CA 2837126 A CA2837126 A CA 2837126A CA 2837126 A CA2837126 A CA 2837126A CA 2837126 A1 CA2837126 A1 CA 2837126A1
- Authority
- CA
- Canada
- Prior art keywords
- virus
- canine influenza
- seq
- recombinant virus
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 103
- 241000282465 Canis Species 0.000 title claims abstract description 84
- 206010022000 influenza Diseases 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 46
- 241000287828 Gallus gallus Species 0.000 claims abstract description 34
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 27
- 230000035931 haemagglutination Effects 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 229960003971 influenza vaccine Drugs 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 36
- 101710154606 Hemagglutinin Proteins 0.000 claims description 30
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 30
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 30
- 101710176177 Protein A56 Proteins 0.000 claims description 30
- 239000000185 hemagglutinin Substances 0.000 claims description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 24
- 125000003729 nucleotide group Chemical group 0.000 claims description 24
- 239000013612 plasmid Substances 0.000 claims description 21
- 239000012530 fluid Substances 0.000 claims description 19
- 239000006228 supernatant Substances 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 101150039660 HA gene Proteins 0.000 claims description 8
- 101150080862 NA gene Proteins 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 210000004748 cultured cell Anatomy 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 108010006232 Neuraminidase Proteins 0.000 description 18
- 238000011081 inoculation Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 13
- 102000005348 Neuraminidase Human genes 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 241000252870 H3N2 subtype Species 0.000 description 8
- 210000002257 embryonic structure Anatomy 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 231100000645 Reed–Muench method Toxicity 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000252869 H3N8 subtype Species 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 108010015268 Integration Host Factors Proteins 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110139528.3 | 2011-05-26 | ||
| CN2011101395283A CN102220293B (zh) | 2011-05-26 | 2011-05-26 | 犬流感重组病毒及其制备方法和应用 |
| PCT/CN2012/074722 WO2012159522A1 (zh) | 2011-05-26 | 2012-04-26 | 犬流感重组病毒及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2837126A1 true CA2837126A1 (en) | 2012-11-29 |
Family
ID=44776999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2837126A Abandoned CA2837126A1 (en) | 2011-05-26 | 2012-04-26 | Canine influenza recombinant virus, preparation method therefor and application thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140286979A1 (enExample) |
| EP (1) | EP2716752A4 (enExample) |
| JP (1) | JP2014516530A (enExample) |
| KR (1) | KR20140031912A (enExample) |
| CN (1) | CN102220293B (enExample) |
| CA (1) | CA2837126A1 (enExample) |
| WO (1) | WO2012159522A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102220293B (zh) * | 2011-05-26 | 2012-12-19 | 中国农业科学院上海兽医研究所 | 犬流感重组病毒及其制备方法和应用 |
| CN103881983B (zh) * | 2014-03-07 | 2016-08-31 | 中国农业科学院哈尔滨兽医研究所 | 重组犬流感病毒毒株、其制备方法及由其制备得到的疫苗 |
| KR101633489B1 (ko) | 2015-02-25 | 2016-06-27 | 고패스 주식회사 | 통풍수단이 구비된 신발의 사출식 제조방법 |
| EP3313440A2 (en) | 2015-06-26 | 2018-05-02 | Merial, Inc. | Inactivated canine influenza vaccines and methods of making and uses thereof |
| CN105647877A (zh) * | 2016-02-02 | 2016-06-08 | 南京农业大学 | 一株低毒力重组猪脑心肌炎病毒及其应用 |
| CN107602697B (zh) * | 2017-08-29 | 2020-05-05 | 杭州医学院 | 一种治疗流感嗜血杆菌引起鼻窦炎的血清及该血清的应用 |
| CN113173976B (zh) * | 2021-06-03 | 2022-07-12 | 北京市农林科学院 | 一种犬流感病毒h3亚型ha蛋白、其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2345716B1 (en) * | 1999-04-06 | 2015-01-14 | Wisconsin Alumni Research Foundation | Recombinant influenza viruses for vaccines and gene therapy |
| CN1261564C (zh) * | 2003-12-02 | 2006-06-28 | 中国农业科学院哈尔滨兽医研究所 | 人工重组的流感病毒及其应用 |
| US7384642B2 (en) * | 2005-08-25 | 2008-06-10 | Merial Limited | Canine influenza vaccines |
| BRPI0617735B1 (pt) * | 2005-10-19 | 2022-05-17 | University Of Florida Research Foundation Inc | Composições compreendendo vírus isolados, polinucleotídeos, ou polipeptídeos, construções de expressão, vacinas, kits para proteger um canino da infecção do vírus influenza, uso do vírus na preparação de composição farmacêutica bem como método in vitro para detecção de um vírus influenza que é capaz de infectar um animal canídeo |
| JP2010539093A (ja) * | 2007-09-10 | 2010-12-16 | インターベツト・インターナシヨナル・ベー・ベー | イヌ、ネコ及びウマにおけるインフルエンザ感染を予防するための組成物及び方法 |
| KR100850545B1 (ko) * | 2007-10-30 | 2008-08-05 | 주식회사 에니멀제네틱스 | 신규한 개 인플루엔자 바이러스 및 이의 백신 |
| CN102220293B (zh) * | 2011-05-26 | 2012-12-19 | 中国农业科学院上海兽医研究所 | 犬流感重组病毒及其制备方法和应用 |
-
2011
- 2011-05-26 CN CN2011101395283A patent/CN102220293B/zh active Active
-
2012
- 2012-04-26 EP EP12790131.2A patent/EP2716752A4/en not_active Withdrawn
- 2012-04-26 CA CA2837126A patent/CA2837126A1/en not_active Abandoned
- 2012-04-26 KR KR1020137031403A patent/KR20140031912A/ko not_active Withdrawn
- 2012-04-26 WO PCT/CN2012/074722 patent/WO2012159522A1/zh not_active Ceased
- 2012-04-26 JP JP2014511717A patent/JP2014516530A/ja active Pending
- 2012-04-26 US US14/119,366 patent/US20140286979A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2716752A4 (en) | 2014-04-30 |
| KR20140031912A (ko) | 2014-03-13 |
| WO2012159522A1 (zh) | 2012-11-29 |
| CN102220293B (zh) | 2012-12-19 |
| EP2716752A1 (en) | 2014-04-09 |
| JP2014516530A (ja) | 2014-07-17 |
| US20140286979A1 (en) | 2014-09-25 |
| CN102220293A (zh) | 2011-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Advances in development and application of influenza vaccines | |
| US11542527B2 (en) | Parainfluenza virus 5 based vaccines | |
| CN115998856B (zh) | 一种新冠流感免疫原性组合物及其制备方法和应用 | |
| JP6042131B2 (ja) | イヌにおける呼吸器疾患管理のための材料および方法 | |
| US20140286979A1 (en) | Canine influenza recombinant virus, preparation method therefor and application thereof | |
| Pérez-Girón et al. | Mucosal polyinosinic-polycytidylic acid improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and T cell immunity | |
| JP2009512449A (ja) | イヌにおける呼吸器疾患管理のための材料および方法 | |
| CN110305898A (zh) | 哺乳动物细胞非易感h9n2亚型冷适应禽流感病毒的拯救 | |
| JP2014511119A (ja) | Ｈ１ｎ１亜型インフルエンザパンデミックウイルスに対する新型ワクチン | |
| CN106117369A (zh) | 融合蛋白sHA1‑Fc及应用 | |
| CN105671002B (zh) | H9n2亚型禽流感病毒细胞高产疫苗株构建及应用 | |
| CN104073470A (zh) | 一种h9n2亚型禽流感病毒的转瓶培养方法 | |
| CN102526718A (zh) | 一种重组h5n1禽流感病毒细胞苗及应用 | |
| KR101908905B1 (ko) | 인플루엔자 바이러스의 h9 및 h5의 다중 아형에 대한 교차 면역반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 백신 | |
| CN103881983B (zh) | 重组犬流感病毒毒株、其制备方法及由其制备得到的疫苗 | |
| CN105087502B (zh) | H9n2亚型禽流感病毒温度敏感性减毒活疫苗候选株ca‑28（ah）及其应用 | |
| JP2015506949A5 (enExample) | ||
| CN117659138B (zh) | 一种流感病毒np蛋白突变体及其应用 | |
| JP6174857B2 (ja) | 外来物質試験 | |
| Liang et al. | Research of Recombinant Influenza A Virus as a Vector for Mycoplasma Pneumoniae P1a and P30a | |
| CN102234636B (zh) | 重组甲型H1N1流感病毒冷适应弱毒活疫苗株(SC/AAca)的制备及应用 | |
| CN115725517A (zh) | 一种h3n2犬流感重组病毒株及其应用 | |
| HK1188736A (en) | Extraneous agents testing | |
| WO2014101210A1 (zh) | 表达小反刍兽疫病毒h蛋白的重组新城疫病毒及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20131122 |
|
| FZDE | Discontinued |
Effective date: 20160427 |